Détail - canceropole-wordpress

Central nervous system complications of immune checkpoint inhibitors: a comprehensive review.

Lopes S, Pabst L, Bahougne T, Barthelemy P, Guitton R, Didier K, Geoffrois L, Granel-Brocard F, Mennecier B, Mascaux C, Kremer S, Collongues N

Crit Rev Oncol Hematol. 2024 12 12;:104595

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S

Lung Cancer. 2024 08 6;196:107921

Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.

Mennecier B, Khalifa J, Descourt R, Greillier L, Naltet C, Falchero L

BMC Cancer. 2024 04 5;24(1):421

18FDG PET/CT Tumoral and Neurologic Therapeutic Response in a Case of Anti-GABABR Paraneoplastic Limbic Encephalitis.

Ouvrard E, Voulleminot P, Mennecier B, Bund C, Namer IJ

Clin Nucl Med. 2023 03 1;48(3):237-239

Immunotherapy and Interventional Radiology: Two Optimal Allies in the Management of Bronchial Cancer.

Mennecier B

Cardiovasc Intervent Radiol. 2022 08 9;:

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.

Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C

Cancers (Basel). 2022 Mar 30;14(7):

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clément-Duchêne C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N

Eur J Cancer. 2022 Mar 9;166:51-59

Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.

Slimano F, Le Bozec A, Cransac A, Foucher P, Lesauvage F, Delclaux B, Dory A, Mennecier B, Bertrand B, Gubeno-Dumon MC, Dukic S, Mongaret C, Bouché O, Hettler D, Boulin M, Dewolf M, Kanagaratnam L

Lung Cancer. 2022 Feb 24;166:114-121

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.

Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Thillays F, Quantin X, Oulkhouir Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game L, Besse B, Girard N

Eur J Cancer. 2021 Dec 26;162:118-127

Re: Two centres' experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes.

Mennecier B, Olland A, Mascaux C, Falcoz PE

Eur J Cardiothorac Surg. 2021 12 1;60(6):1306-1307

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ

Clin. Cancer Res.. 2020 Mar 6;:

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Perol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert AM, Rabbe N, Antoine M, Wislez M

J Thorac Oncol. 2020 Jan 25;:

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G

Ann. Oncol.. 2019 Dec;30(12):1985-1991

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G

Ann. Oncol.. 2019 Oct 4;:

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG

Clin Lung Cancer. 2019 Oct 1;:

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C

Lung Cancer. 2019 Aug 14;136:109-114

Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.

Bender L, Meyer G, Quoix E, Mennecier B

Ann Transl Med. 2019 Mar;7(5):106

Lung resection and immunotherapy: two allied for a new hope in lung cancer cure.

Mennecier B, Olland A, Massard G, Falcoz PE

J Thorac Dis. 2018 Nov;10(Suppl 33):S4168-S4169

Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort.

Domblides C, Monnet I, Mazieres J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Molinier O, Perol M, Pichon E, Robinet G, Templement Grangerat D, Ruppert AM, Wislez M

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii406

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M

Rev Mal Respir. 2018 Sep 19;:

KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.

Renaud S, Guerrera F, Seitlinger J, Reeb J, Voegeli AC, Legrain M, Mennecier B, Santelmo N, Falcoz PE, Quoix E, Chenard MP, Weingertner N, Beau-Faller M, Massard G

Clin Lung Cancer. 2018 Aug 22;:

Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N

J Thorac Oncol. 2018 Aug 20;:

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Emprou C, Le Van Quyen P, Jégu J, Prim N, Weingertner N, Guérin E, Pencreach E, Legrain M, Voegeli AC, Leduc C, Mennecier B, Falcoz PE, Olland A, Santelmo N, Quoix E, Massard G, Guenot D, Chenard MP, Beau-Faller M

Cancer Med. 2018 May 29;:

Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B

ERJ Open Res. 2018 Jan;4(1):

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D

Oncotarget. 2017 Mar;8(13):21903-21917

[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].

Zapata E, Mennecier B, Leduc C, Chatron E, Quoix E

Rev Pneumol Clin. 2016 Oct;72(5):300-304

Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.

Gass-Jégu F, Gschwend A, Gairard-Dory AC, Mennecier B, Tebacher-Alt M, Gourieux B, Quoix É

Lung Cancer. 2016 Sep;99:76-8

Successful treatment with ceritinib after crizotinib induced hepatitis.

Sassier M, Mennecier B, Gschwend A, Rein M, Coquerel A, Humbert X, Alexandre J, Fedrizzi S, Gervais R

Lung Cancer. 2016 May;95:15-6

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M

Future Oncol. 2016 Jan;12(1):59-70

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification.

Weingertner N, Meyer N, Voegeli AC, Guenot D, Renaud S, Massard G, Falcoz PE, Olland A, Mennecier B, Gaub MP, Lindner V, Ghnassia JP, Quoix E, Chenard MP, Beau-Faller M

Pathology. 2015 Jun;47(4):320-8

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS

Lancet Oncol. 2015 Mar;16(3):257-65

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

Toffart AC, Dhalluin X, Girard N, Chouaid C, Audigier-Valette C, Duruisseaux M, Mennecier B, Parrot A, Fournel P, Moro-Sibilot D, Timsit JF

Intensive Care Med. 2015 Jan;41(1):164-5

[Afatinib (BIBW 2992)].

Prim N, Fore M, Mennecier B

Rev Pneumol Clin. 2014 Oct;70(5):279-85

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Prim N, Legrain M, Guerin E, Mennecier B, Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE, Beau-Faller M

Eur Respir Rev. 2014 Sep;23(133):390-2

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation.

Schaller A, Beau-Faller M, Mennecier B, Renaud-Picard B, Weingertner N, Massard G, Quoix E

Case Rep Oncol. 2014 Nov 19;7(3):769-73

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F

Bull Cancer. 2014 Sep;101(9):823-31

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G

Eur Respir J. 2014 Jan;43(1):240-9

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].

Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B,

Rev Mal Respir. 2014 Jan;31(1):91-103

[Hemolytic anemia under erlotinib treatment].

Sakhri L, Mennecier B, Quoix A

Rev Pneumol Clin. 2013 Dec;69(6):345-50

[Bevacizumab in thoracic oncology: results and practical aspects].

Dansin E, Cousin S, Lauridant G, Mennecier B

Rev Pneumol Clin. 2013 Jun;69(3):159-69

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise

Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, Besse B, Brouchet L, Castelnau O, Frappé P, Ferretti GR, Guittet L, Khalil A, Lefebure P, Laurent F, Liebart S, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B, ,

Ann. Oncol.. 2013 Mar;24(3):586-97

Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study.

Enache I, Noel G, Jeung MY, Meyer N, Oswald-Mammosser M, Pistea C, Jung GM, Mennecier B, Quoix E, Charloux A

Respiration. 2013;86(2):100-8

Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed.

Frouin E, Sebille G, Freudenberger S, Menecier B, Quoix E, Cribier B, Lipsker D

Br. J. Dermatol.. 2012 Jun;166(6):1359-60

[Atypical metastatic site of lung adenocarcinoma].

Sakhri L, Mennecier B, Jacqmin D, Di Marco A, Schumacher C, Chenard MP, Bergmann E, Quoix E

Rev Pneumol Clin. 2011 Dec;67(6):375-9

[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].

Quoix E, Ducolone A, Mennecier B, Fraisse P

Presse Med. 2011 Apr;40(4 Pt 1):420-6

[Muscular metastasis from primary lung cancer: about seven cases].

Hajouji L, Mennecier B, de la Haye Saint-Hilaire D, Bierry G, Canuet M, Quoix E

Rev Pneumol Clin. 2011 Apr;67(2):75-81

Clinical Case no. 1 proposed by the E Quoix team (CHRU Strasbourg).

Mennecier B, Paumier A

Rev Pneumol Clin. 2010 Apr;66:3-8.

Clinical no. 4 proposed by the G. Zalcman team (CHU Caen).

Madelaine J, Mennecier B

Rev Pneumol Clin. 2010 Apr;66:19-23.

[Clinical case No. 1 proposed by the E Quoix (CHRU Strasbourg) team].

Mennecier B, Paumier A, Giroux Leprieur E

Rev Pneumol Clin. 2010 Apr;66(2 Suppl 1):H3-8.

[Clinical case No. 4 proposed by the G. Zalcman (CHU Caen) team].

Madelaine J, Mennecier B, Giroux Leprieur E

Rev Pneumol Clin. 2010 Apr;66(2 Suppl 1):H19-23.

[Small cell lung cancer and anti-Hu syndrome]

Prim N, Mennecier B, Behr C, Fraisse P, Echaniz-Laguna A, Tranchant C, Quoix E

Rev Mal Respir. 2010 Mar;27(3):261-5

Clinical case no. 2 proposed by the Strasbourg team

Thibout Y, Mennecier B

Rev Pneumol Clin. 2009 Jun;65:8-13

Clinical case no. 3 proposed by the Tenon team

Mennecier B, Lavole A

Rev Pneumol Clin. 2009 Jun;65:14-8

[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma]

Burgin M, Gairard-Dory AC, Mennecier B, Molard A, Beretz L, Quoix AE

Rev Pneumol Clin. 2009 Apr;65(2):75-83

A two-faced young woman.

Antoni DN, Jeung MY, Mennecier B, Ruppert AM, Massard G, Quoix E

J Thorac Oncol. 2009 Feb;4(2):240-1

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.

Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E

Eur Respir J. 2009 Feb;33(2):436-40.

[Thyroid metastasis of lung cancer and abnormal thyroid function--a case report]

Wirtz G, Quoix E, Grunenberger F, Massard G, Mennecier B

Rev Pneumol Clin. 2009 Feb;65(1):27-31

Lung cancer in the elderly

Quoix E, Mennecier B, Ruppert AM, Fraisse P, Ducolone A

Oncologie. 2008 Sep;10(9):536-9

MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP

J Thorac Oncol. 2008 Apr;3(4):331-9.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M

Ann Oncol. 2008 Feb;19(2):362-9